Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 3, 2014, Pages 355-362

  Haku, J ^a   Nogami, K ^a   Matsumoto, T ^a   Ogiwara, K ^a   Shima, M ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood coagulation factor inhibitors; Clinical laboratory techniques; Factor VIII; Hemophilia A; Hemostatic techniques

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING INHIBITOR; ELLAGIC ACID; REAGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN;

ACCELERATION; ADULT; ARTICLE; BLOOD CLOT; BLOOD CLOTTING; BLOOD CLOTTING TIME; CHILD; CLINICAL ARTICLE; CLINICAL LABORATORY; CLOT WAVEFORM ANALYSIS; CONTROLLED STUDY; EX VIVO STUDY; HEMOPHILIA A; HEMOSTASIS; HEMOSTASIS TESTING SYSTEM; HUMAN; IN VITRO STUDY; MIDDLE AGED; PARAMETERS; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; QUANTITATIVE ASSAY; ROTATIONAL THROMBOELASTOMETRY; SCHOOL CHILD; SYNOVECTOMY; WAVEFORM; YOUNG ADULT;

BLOOD COAGULATION FACTOR INHIBITORS; CLINICAL LABORATORY TECHNIQUES; FACTOR VIII; HEMOPHILIA A; HEMOSTATIC TECHNIQUES;

ADOLESCENT; ADULT; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CHILD; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS; HUMANS; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBOPLASTIN; YOUNG ADULT;

EID: 84896767826     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12488     Document Type: Article

References (20)

1. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haemotologica 2000; 85: 7-13.
2. Hemker HC. The mode of action of heparin in plasma. In: Verstraete M, Vermylen J, Lijnen R, Arnout J, eds. Thrombosis and Haemostasis. Leuven: Leuven University Press, 1987: 17-36.
3. Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
4. Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, Schramm W, Kirchmaier C, Martinowitz U. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. Thromb Haemost 2010; 103: 351-9.
5. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
6. Turecek PL, Váradi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33: 16-22.
7. Dargaud Y, Lienhart A, Meunier S, Hequet O, Chavanne H, Chamouard V, Marin S, Negrier C. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11: 552-8.
8. Keularts IM, Zivelin A, Seligsohn U, Hemker HC, Béguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001; 85: 1060-5.
9. van Veen JJ, Gatt A, Cooper PC, Kitchen S, Bowyer AE, Makris M. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters. Blood Coagul Fibrinolysis 2008; 19: 183-9.
10. Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol 2009; 90: 576-82.
11. Braun PJ, Givens TB, Stead AG, Beck LR, Gooch SA, Swan RJ, Fischer TJ. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 78: 1079-87.
12. Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, Giles AR, Yoshioka A. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002; 87: 436-41.
13. Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, Giles AR, Yoshioka A. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006; 4: 377-84.
14. Shima M, Thachil J, Nair SC, Srivastava A. Towards standardization of the clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost 2013; 11: 1417-20.
15. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-40.
16. van Veen JJ, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. Int J Lab Hematol 2009; 31: 189-98.
17. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
18. Matsumoto T, Nogami K, Ogiwara K, Shima M. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost 2012; 107: 288-301.
19. Hemker HC, Béguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
20. Dargaud Y, Béguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.